Balyasny Asset Management L.P. Invests $2.14 Million in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Balyasny Asset Management L.P. purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 38,488 shares of the specialty pharmaceutical company's stock, valued at approximately $2,138,000. Balyasny Asset Management L.P. owned about 0.18% of ANI Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Exchange Traded Concepts LLC raised its holdings in shares of ANI Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock worth $684,000 after buying an additional 310 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock worth $246,000 after buying an additional 412 shares during the last quarter. Natixis Advisors LLC raised its holdings in shares of ANI Pharmaceuticals by 2.3% in the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock worth $1,028,000 after buying an additional 417 shares during the last quarter. US Bancorp DE raised its holdings in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares during the last quarter. Finally, KBC Group NV raised its holdings in shares of ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after purchasing an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ANIP shares. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price for the company. Guggenheim reissued a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a report on Monday, May 12th. HC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. StockNews.com cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Finally, Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a report on Monday, April 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $80.13.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP traded up $0.46 on Friday, hitting $59.99. The company's stock had a trading volume of 372,976 shares, compared to its average volume of 298,906. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $77.00. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -109.07 and a beta of 0.56. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock has a 50 day moving average of $66.91 and a 200-day moving average of $60.79.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. During the same quarter in the prior year, the firm posted $0.82 earnings per share. The company's quarterly revenue was up 43.4% compared to the same quarter last year. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $60.07, for a total transaction of $52,921.67. Following the sale, the senior vice president now owns 89,897 shares in the company, valued at $5,400,112.79. This trade represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 7,681 shares of company stock valued at $468,698. Corporate insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.